Phase I dose‐escalation study of buparlisib ( BKM 120), an oral pan‐class I PI 3K inhibitor, in Japanese patients with advanced solid tumors-Reference-Cited by-同舟云学术

Phase I dose‐escalation study of buparlisib ( BKM 120), an oral pan‐class I PI 3K inhibitor, in Japanese patients with advanced solid tumors

Published:2014-02-13 Issue:3 Volume:105 Page:347-353
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Ando Yuichi¹,Inada‐Inoue Megumi¹,Mitsuma Ayako¹,Yoshino Takayuki²,Ohtsu Atsushi²,Suenaga Naoko³,Sato Masahiko³,Kakizume Tomoyuki³,Robson Matthew³,Quadt Cornelia⁴,Doi Toshihiko²

Affiliation:

1. Nagoya University Hospital NagoyaJapan

2. National Cancer Center Hospital East KashiwaJapan

3. Novartis Pharma K.K. Tokyo Japan

4. Novartis Pharmaceuticals East Hanover New Jersey USA

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12350

Reference50 articles.

1. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

2. Targeting the phosphoinositide 3-kinase pathway in cancer

3. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity

4. Induction of Akt Activity by Chemotherapy Confers Acquired Resistance

5. Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma;Biomedicines;2024-07-19

2. An adipoincretin effect links adipostasis with insulin secretion;Trends in Endocrinology & Metabolism;2024-06

3. What Do German Molecular Tumor Boards Recommend in Patients with PIK3CA-Mutated Tumors? Launch and First Results from the German Transsectoral Molecular Tumor Board Exchange Platform Deutschland;Oncology Research and Treatment;2024-05-07

4. Adipocyte PI3K links adipostasis with baseline insulin secretion at fasting through an adipoincretin effect;Cell Reports;2024-05

5. Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment;Molecules;2023-11-09